<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05068583</url>
  </required_header>
  <id_info>
    <org_study_id>CHLA-19-00146</org_study_id>
    <nct_id>NCT05068583</nct_id>
  </id_info>
  <brief_title>Liquid Biopsies in Pediatric Solid Tumors</brief_title>
  <official_title>Liquid Biopsies in Non-CNS Malignant Pediatric Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to determine if traces of tumor can be found in the blood before,&#xD;
      during, and after patients stop treatment. We will analyze the tumor material to see if it is&#xD;
      similar to tumor tissue and if the tumor material in blood is helpful in monitoring the&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Liquid biopsies, particularly those involving cell-free DNA (cfDNA), are a promising&#xD;
      non-invasive, cost effective method of monitoring disease in cancer patients with solid&#xD;
      tumors and are being increasingly employed in various adult malignancies to diagnose disease,&#xD;
      monitor tumor response, detect relapse and learn more about tumor biology. The utility of&#xD;
      liquid biopsies which may include isolation and analysis of tumor derived material such as&#xD;
      DNA, RNA, intact cells, proteins, or exosomes from blood or other bodily fluids in pediatric&#xD;
      solid tumors has not been established. In this study, we propose to prospectively collect&#xD;
      serial blood samples at baseline, during therapy, end of therapy, relapse, and during follow&#xD;
      up from patients â‰¥ 6 months of age with newly diagnosed or relapsed/refractory various&#xD;
      pediatric non-CNS malignant solid tumors to determine the feasibility of detecting various&#xD;
      tumor-derived material, including exosomes, circulating tumor cells, and circulating tumor&#xD;
      nucleic acid (ctDNA and ctRNA). The timing of blood sample collection will be during a&#xD;
      routine lab draw around the time of a disease evaluation. The ctDNA and ctRNA as well as DNA&#xD;
      and RNA extracted from tumor-derived exosomes will be quantified at each time point and the&#xD;
      findings will be correlated with conventional methods for disease evaluation (e.g., imaging&#xD;
      studies, histologic tumor response, or serum tumor markers) and outcome (overall survival and&#xD;
      event-free survival).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2019</start_date>
  <completion_date type="Anticipated">May 8, 2034</completion_date>
  <primary_completion_date type="Anticipated">May 8, 2029</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To detect circulating tumor DNA (ctDNA) in serial blood samples from patients with pediatric non-CNS solid tumors using low pass whole genome sequencing.</measure>
    <time_frame>10 years</time_frame>
    <description>To determine the feasibility of detecting circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and circulating tumor RNA (ctRNA) in serial blood samples from patients with newly diagnosed and relapsed/refractory malignant pediatric solid tumors</description>
  </primary_outcome>
  <number_of_groups>10</number_of_groups>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Pediatric Solid Tumor, Unspecified, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Osteosarcoma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Ewing Sarcoma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Rhabdomyosarcoma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Synovial Sarcoma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Rhabdomyosarcoma Soft Tissue Sarcoma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatic Tumors</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Renal Tumors</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Thyroid Tumors</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Germ Cell Tumors</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Draw</intervention_name>
    <description>Blood draw at baseline, disease evaluation time point, and pre and post surgery and/or radiation.</description>
    <arm_group_label>Ewing Sarcoma</arm_group_label>
    <arm_group_label>Germ Cell Tumors</arm_group_label>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_label>Hepatic Tumors</arm_group_label>
    <arm_group_label>Non-Rhabdomyosarcoma Soft Tissue Sarcoma</arm_group_label>
    <arm_group_label>Osteosarcoma</arm_group_label>
    <arm_group_label>Renal Tumors</arm_group_label>
    <arm_group_label>Rhabdomyosarcoma</arm_group_label>
    <arm_group_label>Synovial Sarcoma</arm_group_label>
    <arm_group_label>Thyroid Tumors</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients over the age of 6 months who are newly diagnosed, relapsed, or refractory&#xD;
        histologically confirmed high grade bone or soft tissue sarcoma or malignant renal,&#xD;
        thyroid, germ cell, or hepatic tumors. Also, healthy individuals with no history of cancer&#xD;
        or chronic medical problems who are &lt; 21 years of age.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed, relapsed, or refractory histologically confirmed high grade bone or&#xD;
             soft tissue sarcoma or malignant renal, thyroid, germ cell, or hepatic tumors, OR&#xD;
&#xD;
          -  Healthy individual with no history of cancer or chronic medical problems and &lt; 21&#xD;
             years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CNS Malignancies&#xD;
&#xD;
          -  Individuals &lt; 6 months of age&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fariba Navid, MD</last_name>
    <phone>323-361-2529</phone>
    <email>fnavid@chla.usc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anya Zdanowicz</last_name>
      <phone>323-361-5418</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 30, 2021</study_first_submitted>
  <study_first_submitted_qc>September 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2021</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital Los Angeles</investigator_affiliation>
    <investigator_full_name>Fariba Navid</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

